Does Blue Cross Blue Shield of Arizona Cover Semaglutide (Wegovy)?

What BCBSAZ Plans Actually Cover for Wegovy

BCBSAZ does not publish a single blanket policy for semaglutide 2.4 mg (Wegovy). Coverage is determined at the plan level, which means your employer group plan, ACA marketplace plan, or individual plan may each have different formulary decisions. The FDA approved Wegovy in June 2021 based on the STEP clinical trial program, and the drug carries a labeled indication for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher in the presence of at least one weight-related condition. 1

Commercial Group Plans

Employer-sponsored BCBSAZ group plans have the most variability. Self-funded employer plans, which fall under ERISA rather than Arizona state insurance law, can exclude obesity medications entirely. Fully insured group plans sold in Arizona must follow state-mandated benefits to a greater degree, though Arizona does not currently mandate coverage for GLP-1 weight-loss drugs. If your plan documents list an obesity-drug exclusion, prior authorization approval is unlikely without a formal exception request.

ACA Marketplace Plans

ACA marketplace plans sold by BCBSAZ must cover a set of essential health benefits, but weight-loss drugs are not classified as an essential health benefit under the Affordable Care Act. 2 Individual marketplace plans therefore frequently exclude Wegovy or place it on a specialty tier with high cost-sharing.

Medicare Advantage and Part D

Medicare Part D has historically excluded drugs used primarily for weight loss or gain under 42 U.S.C. 1395w-102(e)(2). 3 The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with pre-existing cardiovascular disease and overweight or obesity, 4 which prompted CMS to evaluate whether Wegovy could be covered under the cardiovascular indication. As of this writing, routine Part D coverage for weight loss specifically remains excluded, but BCBSAZ Medicare Advantage members with cardiovascular disease may wish to contact member services directly, as plan-level formulary decisions are evolving.

AHCCCS (Arizona Medicaid)

Arizona's Medicaid program, the Arizona Health Care Cost Containment System (AHCCCS), contracts with managed care organizations. Coverage for Wegovy under AHCCCS is inconsistent. Members enrolled in AHCCCS managed care plans should contact their specific plan to verify formulary inclusion before any prescription is written.

Prior Authorization Requirements for Wegovy at BCBSAZ

Prior authorization is required on essentially every BCBSAZ plan that does list Wegovy on its formulary. The criteria below reflect published BCBSAZ clinical coverage guidelines and standard GLP-1 prior authorization benchmarks; your specific plan may add or modify criteria.

Standard Clinical Criteria

Most BCBSAZ prior authorization requests for Wegovy must document:

• A BMI of 30 or higher, or a BMI of 27 or higher with at least one of the following comorbidities: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. 5
• A prior attempt at lifestyle modification, typically defined as participation in a structured diet and exercise program for at least 6 months with documented inadequate response.
• An absence of contraindications including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Prescribing by or in consultation with a physician, nurse practitioner, or physician assistant actively managing the patient's obesity or related comorbidities.

Step Therapy

Step therapy requirements vary. Some BCBSAZ plans require documented failure of orlistat 120 mg three times daily before approving Wegovy. Others require only documented lifestyle intervention failure. When your prescriber submits the prior authorization, the request should explicitly address each step-therapy criterion in writing, including dates of prior treatments and outcomes.

Quantity Limits and Ongoing Authorization

BCBSAZ typically authorizes Wegovy for an initial period of 12 to 16 weeks. Continued authorization usually requires documentation of at least a 4% to 5% reduction in body weight from baseline, which aligns with the Endocrine Society clinical practice guideline threshold for assessing pharmacotherapy response. 6 If weight-loss response is insufficient, the plan may not reauthorize the prescription.

The Clinical Case for Coverage: Why This Drug Meets Medical Necessity Standards

Insurance coverage decisions are easier to support when the prescribing physician builds a strong medical necessity argument grounded in published evidence. The STEP clinical trial program is the primary evidence base for semaglutide 2.4 mg.

STEP-1 Trial Results

STEP-1 (N=1,961) randomized adults without diabetes to semaglutide 2.4 mg weekly or placebo alongside lifestyle intervention. At 68 weeks, semaglutide produced a mean weight loss of 14.9% vs. 2.4% with placebo (P<0.001). 7 Participants with a baseline BMI as low as 27 with a comorbidity were included, which maps directly onto the BCBSAZ eligibility criteria.

STEP-4 Sustained Weight Loss Data

STEP-4 (N=803) showed that participants who continued semaglutide 2.4 mg after a 20-week run-in maintained a further 7.9% weight reduction at 48 weeks, while those switched to placebo regained 6.9% of body weight. 8 This data supports the medical necessity argument for ongoing authorization rather than a single short course.

Cardiovascular Outcomes: SELECT Trial

The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a median follow-up of 33.3 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). 4 For patients with existing cardiovascular disease, this outcome data may support a separate medical necessity argument beyond weight loss alone.

Guideline Endorsements

The American Gastroenterological Association issued a clinical practice guideline in 2022 recommending GLP-1 receptor agonists as a first-line pharmacotherapy option for adults with obesity. 9 The Endocrine Society similarly states that pharmacotherapy should be offered to patients with a BMI of 30 or higher, or 27 or higher with complications, when lifestyle intervention alone has not produced adequate weight loss. 6

The Endocrine Society guideline states directly: "We recommend weight-loss pharmacotherapy as an adjunct to lifestyle modification for people with obesity (BMI ≥30) or overweight (BMI 27.0 to 29.9) with weight-related comorbidities who have not achieved weight loss goals through lifestyle modification." 6

How to Submit a Prior Authorization Request That Gets Approved

A prior authorization denial is not necessarily final. The submission quality matters as much as the clinical facts.

What Your Prescriber Should Include

The prior authorization packet sent to BCBSAZ should contain:

• Complete height, weight, and calculated BMI on the date of the visit.
• Documentation of all comorbidities with ICD-10 codes (E11 for type 2 diabetes, I10 for hypertension, E78.5 for mixed hyperlipidemia, G47.33 for obstructive sleep apnea).
• A narrative summary of prior weight-loss attempts, including diet programs, start and end dates, starting and ending weights, and why each attempt was inadequate.
• Laboratory data where relevant, such as HbA1c, fasting glucose, lipid panel, and blood pressure readings.
• A statement directly quoting the Endocrine Society or AGA guideline language that supports pharmacotherapy initiation.
• The NDC number for Wegovy (semaglutide injection 2.4 mg/0.75 mL subcutaneous pen).

Peer-to-Peer Review

If BCBSAZ denies the prior authorization, your prescriber can request a peer-to-peer telephone review with the BCBSAZ medical director responsible for the decision. Peer-to-peer calls reverse a meaningful proportion of initial denials. The prescriber should prepare a concise 5-minute summary citing STEP-1 weight loss data, SELECT cardiovascular outcomes, and the specific guideline language from the Endocrine Society recommendation. 6

Appealing a Denial from BCBSAZ

Every BCBSAZ member has federal and state-law rights to appeal coverage denials.

Internal Appeal

You or your physician may file an internal appeal within 180 days of receiving a denial notice. BCBSAZ must respond to an urgent appeal within 72 hours and a standard appeal within 30 days. The appeal letter should cite the specific plan exclusion language (or its absence), the FDA-approved indication, the STEP-1 and SELECT trial data, and any Endocrine Society or AGA guideline language supporting pharmacotherapy. 7 4

External Independent Review

If the internal appeal is upheld, Arizona law (A.R.S. Section 20-2537) entitles you to an independent external review by a state-certified independent review organization. External reviewers are bound by medical evidence and clinical guidelines rather than formulary decisions. The SELECT cardiovascular outcomes data gives patients with pre-existing cardiovascular disease a particularly strong external review argument.

State Insurance Complaints

The Arizona Department of Insurance and Financial Institutions (DIFI) accepts complaints about improper claim denials. Filing a complaint sometimes prompts BCBSAZ to re-examine a decision more carefully.

Cost Without Insurance: What You Will Actually Pay

If coverage is denied or your plan excludes obesity medications entirely, you have several cost-reduction options.

Novo Nordisk WeightLoss.com Savings Card

Novo Nordisk offers a savings card for commercially insured patients who do not have coverage for Wegovy. Eligible patients may pay as little as $0 per month, subject to a monthly savings cap and program eligibility rules. The card does not apply to Medicare, Medicaid, or CHIP beneficiaries. Terms change periodically, so confirm directly at the Novo Nordisk Wegovy savings page.

Compounded Semaglutide

The FDA placed semaglutide on the drug shortage list in 2022, which allowed licensed 503A and 503B compounding pharmacies to prepare semaglutide. As of early 2024, the FDA removed injectable semaglutide from the shortage list. 10 Patients considering compounded semaglutide should confirm current shortage status with the FDA drug shortage database and discuss safety and purity considerations with their prescriber before switching from a commercially manufactured product.

Telehealth Platforms and Cash-Pay Programs

Cash-pay telehealth programs may offer semaglutide at lower per-month costs than the Wegovy list price, particularly for patients who do not qualify for the Novo Nordisk savings card. These programs typically use compounded semaglutide or, in some cases, the lower-dose Ozempic brand (approved for type 2 diabetes, not for weight management specifically). Using Ozempic off-label for weight loss may affect coverage and involves a different set of prior authorization criteria.

HealthRX Decision Framework: What to Do Based on Your BCBSAZ Plan Type

The path to coverage differs by plan type. Use this structured approach.

Step 1: Identify Your Plan Type

Pull your Summary of Benefits and Coverage (SBC) document. Check the "Excluded Services" section for any language referencing "weight loss drugs," "obesity medications," or "anti-obesity pharmacotherapy." If no exclusion appears, Wegovy may be coverable with prior authorization.

Step 2: Check the Formulary

Log in to your BCBSAZ member portal and search for "semaglutide" or "Wegovy" in the drug lookup tool. Note the formulary tier and any listed restrictions such as prior authorization (PA), step therapy (ST), or quantity limits (QL).

Step 3: Schedule a Prescriber Visit Focused on Documentation

Ask your prescriber to document BMI, comorbidities with ICD-10 codes, and a prior weight-loss history narrative at the visit. A visit focused on weight management and obesity (ICD-10 E66.9 or E66.01) is more likely to generate an approvable PA than a visit where weight is a secondary complaint. The Endocrine Society recommends that prescribers treating obesity use a structured assessment that includes BMI, waist circumference, and comorbidity burden. 6

Step 4: Submit PA and Track the Clock

After submission, BCBSAZ has 15 calendar days for a standard prior authorization determination under Arizona law. Track the submission date. If no decision arrives within that window, the delay itself may be appealable.

Step 5: If Denied, Appeal Immediately

Do not wait. File the internal appeal within the 180-day window and simultaneously ask your prescriber to schedule a peer-to-peer call. Both processes can run in parallel.

Semaglutide for Type 2 Diabetes: A Different Coverage Path

Patients who have type 2 diabetes and obesity face a different formulary situation. Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) is FDA-approved for glycemic control in type 2 diabetes and is much more widely covered by BCBSAZ plans than Wegovy. 11 The ADA Standards of Care recommend GLP-1 receptor agonists as a preferred add-on to metformin when cardiovascular disease, heart failure, or chronic kidney disease is present, or when additional weight loss is needed. 12

Patients with type 2 diabetes and a BMI of 27 or higher who need both glycemic control and weight loss should discuss Ozempic coverage with their prescriber as a potentially more accessible first step. Ozempic at 1 mg weekly produced a mean weight reduction of 6.9% in the SUSTAIN-6 trial (N=3,297) over 104 weeks, 13 a clinically meaningful but smaller reduction than the 14.9% seen with Wegovy at 2.4 mg in STEP-1. 7

What Counts as Medical Necessity: A Clinical Perspective

BCBSAZ, like most major insurers, defines medical necessity as treatment that is appropriate, needed, and consistent with evidence-based clinical standards. For Wegovy, a compelling medical necessity argument rests on three pillars.

First, the patient's BMI and comorbidity profile match the FDA-approved indication. 1 Second, lifestyle modification alone has not produced adequate weight reduction, typically defined as less than 5% body-weight loss over 6 months of structured intervention. Third, untreated obesity poses a documented, specific risk to the patient, whether cardiovascular, metabolic, or musculoskeletal.

The SELECT trial makes the cardiovascular risk argument particularly concrete: obese patients with pre-existing cardiovascular disease face a 20% higher composite MACE risk that semaglutide demonstrably reduces over a 33-month follow-up. 4 A well-constructed letter of medical necessity for a BCBSAZ appeal should quantify that risk in the specific patient, not just reference the trial abstractly.

The American Heart Association's 2021 scientific statement on obesity and cardiovascular disease explicitly describes obesity as a major modifiable cardiovascular risk factor requiring active pharmacologic and lifestyle intervention in appropriate patients. 14 Citing this statement alongside STEP-1 and SELECT data creates a multi-source evidentiary record that is harder for a plan to dismiss.